• E-mail
  • Print
  • Comment
  • Font Size
  • Digg
  • del.icio.us
  • Discuss article

GlaxoSmithKline Granted European Approval for Lung Cancer Drug

Posted on: Tuesday, 13 May 2008, 09:01 CDT

GlaxoSmithKline has announced that oral Hycamtin has received approval from the European Commission, for the treatment of patients with relapsed small cell lung cancer for whom re-treatment with the first-line regimen is not considered appropriate.

The approval was based on positive results from a Phase III study comparing topotecan hard capsules plus best supportive care (BSC ) to BSC alone in patients with relapsed small cell lung cancer (SCLC), in addition to Phase II and Phase III supporting studies.

Eddie Gray, president, pharmaceuticals Europe, GlaxoSmithKline (GSK), said: "Topotecan hard capsules provide physicians and patients with an alternative, effective treatment, with the added convenience of being administered orally."


Source: Datamonitor

More News in this Category


Related Articles



Rating: 3.0 / 5 (7 votes)
Rate this article:
1/52/53/54/55/5

User Comments (0)

Comment on this article

Your Name
Text from the image
Comment
max 1200 chars
* All fields are required